May Guo About mRNA Based in Vivo MG1113 Antibody Production as a Potential Therapeutic Approach for Hemophilia
May Guo, Vice President of Business Development at Biomay AG and Founder and CEO of Novaribo Consulting, shared a post on her LinkedIn account:
“mRNA/LNP encoding MG1113, a humanized monoclonal antibody that targets tissue factor pathway inhibitor (TFPI), to treat hemophilia. This paper shows that a single IV dose of mRNA-LNP achieves substantially higher peak serum concentrations of MG1113 antibody compared with direct antibody administration, demonstrating the pharmacokinetic advantage of mRNA-encoded antibody delivery.”
Title: mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia
Authors: Miyoung Oh, Yujeong Jeong, Hyein Jung, Yongjoo Byeon, Heechun Kwak, Songseop Kim, Wonhyo Seo, Jaesung Jung, Hyukjin Lee
Find more posts on Hemostasis Today.
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs
-
Mar 18, 2026, 16:07Scott Isaacs: Optimizing Brain Vitality and Slowing Neurodegeneration Through Daily Habits